Skip to main content
Clinical Trials/NCT04842123
NCT04842123
Completed
Not Applicable

Electrocardiogram Clinical Validation Study

Garmin International6 sites in 1 country568 target enrollmentMarch 31, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Atrial Fibrillation
Sponsor
Garmin International
Enrollment
568
Locations
6
Primary Endpoint
Specificity of rhythm classification
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

The purpose of the study is to confirm the Garmin ECG (electrocardiogram) software algorithm can detect and classify atrial fibrillation and normal sinus rhythm on single lead ECG data derived from a Garmin wrist-worn, consumer device. The study will also confirm the software's ability to create a Lead I ECG that is clinically equivalent to a reference device. The Garmin ECG software is not a diagnostic system and is intended for informational purposes only.

Registry
clinicaltrials.gov
Start Date
March 31, 2021
End Date
October 4, 2021
Last Updated
4 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Garmin International
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Able to read, understand, and provide written informed consent;
  • Willing and able to participate in the study procedures as described in the consent form;
  • Individuals who are 22 years of age and older;
  • Able to communicate effectively with and follow instructions from the study staff;
  • Have a wrist circumference that fits within the device band; and
  • For subjects enrolled into the AF population, subjects must have a known diagnosis of AF and be in AF at the time of screening.

Exclusion Criteria

  • Physical disability that precludes safe and adequate testing;
  • Mental impairment resulting in limited ability to cooperate;
  • Subjects with a pacemaker or implantable cardioverter-defibrillator (ICD);
  • Acute myocardial infarction within 90 days of screening or other cardiovascular disease that, in the opinion of the Investigator, increases the risk to the subject or renders data uninterpretable;
  • Acute pulmonary embolism, pulmonary infarction, or deep vein thrombosis within 90 days of screening;
  • Stroke or transient ischemic attack within 90 days of screening;
  • Subjects taking rhythm control drugs;
  • Symptomatic (or active) allergic skin reactions such as eczema, rosacea, impetigo, dermatomyositis, or allergic contact dermatitis on both wrists or over electrode attachment sites, including known allergy or sensitivity to silicone bands primarily used in wrist-worn fitness devices;
  • Known sensitivity to medical adhesives, isopropyl alcohol, watch bands, or ECG electrodes;
  • A history of abnormal life-threatening rhythms as determined by the Investigator;

Outcomes

Primary Outcomes

Specificity of rhythm classification

Time Frame: 1 Day

Number of participants with a SR software rhythm classification in agreement with a physician's interpretation of heart rhythm based on gold standard 12-lead ECG

Sensitivity of rhythm classification

Time Frame: 1 Day

Number of participants with an AF software rhythm classification in agreement with a physician's interpretation of heart rhythm based on gold standard 12-lead ECG

Secondary Outcomes

  • Number of ECGs that pass a visual overlay(Day 1)
  • Difference in R-wave amplitudes between the software and gold standard reference(Day 1)

Study Sites (6)

Loading locations...

Similar Trials